Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2022 Jan 26.

Published in final edited form as: ACS Nano. 2020 Dec 22;15(1):1608–1626. doi: 10.1021/acsnano.0c09206

Figure 3. — TNP pretreatment interferes in OVA-induced antibody responses in a murine sensitization model. (A) Outline of the experimental animal protocol. Six to eight week old C57/BL6 mice received IV injection of NP^OVA to deliver 25 μg OVA in 500 μg particles per animal on days 0 and 7. The animals were subsequently sensitized with two doses of OVA (10 μg/mouse) IP on days 14 and 21, before being exposed to aerosolized OVA inhalation (10 mg/mL) for 20 min on days 35-37. Animals were sacrificed for tissue harvesting and collection of BALF on day 40. The treatment groups (n=6) in the experiment included: (i) a control group without NP pretreatment, sensitization or challenge; (ii) no pretreatment before sensitization and challenge, or pretreatment with :(iii) NP^OVA, (iv) NP^OVA/ApoBP, (v)NP^Curcumin+free OVA, (vi) NP^OVA-Curcumin, (vii) NP^Rapa+free OVA, (viii) NP^OVA-Rapa before sensitization and challenge. (B) Serum anti-OVA IgE, IgG₁, and IgG_2a antibody titers, as determined by ELISA. Data are expressed as the mean ± SEM. *p < 0.05; **p < 0.01; ***p < 0.001 (one-way ANOVA followed by a Tukey’s test).

Figure 3. — TNP pretreatment interferes in OVA-induced antibody responses in a murine sensitization model. (A) Outline of the experimental animal protocol. Six to eight week old C57/BL6 mice received IV injection of NP^OVA to deliver 25 μg OVA in 500 μg particles per animal on days 0 and 7. The animals were subsequently sensitized with two doses of OVA (10 μg/mouse) IP on days 14 and 21, before being exposed to aerosolized OVA inhalation (10 mg/mL) for 20 min on days 35-37. Animals were sacrificed for tissue harvesting and collection of BALF on day 40. The treatment groups (n=6) in the experiment included: (i) a control group without NP pretreatment, sensitization or challenge; (ii) no pretreatment before sensitization and challenge, or pretreatment with :(iii) NP^OVA, (iv) NP^OVA/ApoBP, (v)NP^Curcumin+free OVA, (vi) NP^OVA-Curcumin, (vii) NP^Rapa+free OVA, (viii) NP^OVA-Rapa before sensitization and challenge. (B) Serum anti-OVA IgE, IgG₁, and IgG_2a antibody titers, as determined by ELISA. Data are expressed as the mean ± SEM. *p < 0.05; **p < 0.01; ***p < 0.001 (one-way ANOVA followed by a Tukey’s test).